Low-volume bowel preparation provides safe and effective pan-enteric capsule endoscopy in suspected or established Crohn’s disease

Table 6 Clinical and demographic characteristics of the individual participant data meta-analysis, n (%)

	LVP (n = 55)	Combined HVP (n = 257)	P value
Sex
Male	22/55 (40.0)	103/257 (40.1)	0.104
Female	33/55 (60.0)	135/257 (52.5)
Unknown	0/55 (0.0)	19/257 (7.4)
CD status1
Active CD	23 (41.8)	195 (75.9)	< 0.001b
CD in remission	19 (34.5)	58 (22.6)
Suspected CD	13 (23.6)	4 (1.6)
Montreal classification1
Age at diagnosis
> 16	2/41 (4.9)	10/126 (7.9)	0.513
17-40	30/41 (73.2)	97/126 (77.0)
> 40	9/41 (22.0)	19/126 (15.1)
Location
L1	24/42 (57.1)	73/168 (43.5)	0.269
L2	3/42 (7.1)	19/168 (11.3)
L3	15/42 (35.7)	76/168 (45.2)
L4	0/42 (0.0)	0/168 (0.0)
Behavior1
Inflammatory	32/42 (76.2)	121/168 (72.0)	0.840
Structuring	7/42 (16.7)	31/168 (18.5)
Penetrating	3/42 (7.1)	16/168 (9.0)
Current treatment1
5-ASA	8/55 (14.5)	21/172 (12.2)	0.651
Immunomodulatory	6/55 (10.9)	44/172 (25.6)	0.025a
Biologic	21/55 (38.2)	98/172 (57.0)	0.020a

^aP < 0.05.

^bP < 0.01.

¹Data was analyzed only among patients with established Crohn’s disease.

LVP: Low-volume protocol; HVP: High-volume protocol; 5-ASA: 5-aminosalicylic acid; CD: Crohn’s disease.